SE0101982D0 - Pharmaceutical combination - Google Patents

Pharmaceutical combination

Info

Publication number
SE0101982D0
SE0101982D0 SE0101982A SE0101982A SE0101982D0 SE 0101982 D0 SE0101982 D0 SE 0101982D0 SE 0101982 A SE0101982 A SE 0101982A SE 0101982 A SE0101982 A SE 0101982A SE 0101982 D0 SE0101982 D0 SE 0101982D0
Authority
SE
Sweden
Prior art keywords
ethoxy
pharmaceutical combination
phenyl
propanoic acid
methanesulfonyloxyphenyl
Prior art date
Application number
SE0101982A
Other languages
English (en)
Swedish (sv)
Inventor
Peter Oehman
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0101982A priority Critical patent/SE0101982D0/xx
Publication of SE0101982D0 publication Critical patent/SE0101982D0/xx
Priority to IL15903502A priority patent/IL159035A0/xx
Priority to PCT/SE2002/001036 priority patent/WO2002100413A1/en
Priority to PL02367890A priority patent/PL367890A1/xx
Priority to EEP200300583A priority patent/EE200300583A/xx
Priority to RU2003136157/15A priority patent/RU2003136157A/ru
Priority to CA002448763A priority patent/CA2448763A1/en
Priority to SK1472-2003A priority patent/SK14722003A3/sk
Priority to JP2003503234A priority patent/JP2004532891A/ja
Priority to BR0210127-0A priority patent/BR0210127A/pt
Priority to KR10-2003-7015644A priority patent/KR20040007624A/ko
Priority to EP02736370A priority patent/EP1399166A1/en
Priority to HU0401613A priority patent/HUP0401613A3/hu
Priority to MXPA03011010A priority patent/MXPA03011010A/es
Priority to CNB028149882A priority patent/CN1250226C/zh
Priority to CZ20033235A priority patent/CZ20033235A3/cs
Priority to US10/479,205 priority patent/US20040157927A1/en
Priority to NO20035235A priority patent/NO20035235D0/no
Priority to ZA200309263A priority patent/ZA200309263B/en
Priority to IS7057A priority patent/IS7057A/is
Priority to CO03112113A priority patent/CO5540382A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE0101982A 2001-06-01 2001-06-01 Pharmaceutical combination SE0101982D0 (sv)

Priority Applications (21)

Application Number Priority Date Filing Date Title
SE0101982A SE0101982D0 (sv) 2001-06-01 2001-06-01 Pharmaceutical combination
US10/479,205 US20040157927A1 (en) 2001-06-01 2002-05-30 Pharmaceutical combination comprising either (s)-2-ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{-4-[2-(4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and a sulonylurea
JP2003503234A JP2004532891A (ja) 2001-06-01 2002-05-30 （Ｓ）−２−エトキシ−３−［４−（２−｛４−メタンスルホニルオキシフェニル｝エトキシ）フェニル］プロパン酸かまたは３−｛４−［２−（４−ｔｅｒｔ−ブトキシカルボニルアミノフェニル）エトキシ］フェニル｝−（Ｓ）−２−エトキシプロパン酸およびスルホニル尿素を含む医薬組合せ
KR10-2003-7015644A KR20040007624A (ko) 2001-06-01 2002-05-30 (Ｓ)-2-에톡시-3-[4-(2-｛4-메탄설포닐옥시페닐｝에톡시)페닐] 프로판산 또는3-｛4-[2-(4-ｔ-부톡시카르보닐아미노페닐)에톡시]페닐｝-(Ｓ)-2-에톡시 프로판산 및 설포닐우레아를 포함하는 약학조합물
PL02367890A PL367890A1 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3- 4-(2- 4-methane sulfonyl oxyphenyl ethoxy) phenyl] propanoic acid or 3- 4- 2-(4-tert- butoxy carbonyl aminophenyl) ethoxy] phenyl -(s)-2-ethoxy propanoic acid and a sulonylurea
EEP200300583A EE200300583A (et) 2001-06-01 2002-05-30 Ravimikombinatsioon, mis sisaldab kas (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhapet või 3-{4-[2-(4-tert-butoksükarbonüülaminofenüül)etoksü]fenüül}-(S)-2-etoksüpropaanhapet ja sulfonüüluureat
RU2003136157/15A RU2003136157A (ru) 2001-06-01 2002-05-30 Фармацевтическая комбинация, содержащая либо (s)-2-этокси-3-{4-метансульфонилоксифенил}-пропионовую кислоту, либо 3-{4-[2-(4-трет-бутоксикарбониламинофенил) этокси]фенил}-(s)-этоксипропионовую кислоту и сульфонилмочевину
CA002448763A CA2448763A1 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tert- butoxy carbonyl aminophenyl)ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a sulonylurea
SK1472-2003A SK14722003A3 (sk) 2001-06-01 2002-05-30 Farmaceutická kombinácia obsahujúca buď kyselinu (S)-2-etoxy-3- [4-(2-{4-metánsulfonyloxyfenyl}-etoxy)fenyl]propánovú, alebo kyselinu 3-{4-[2-(4-terc-butoxykarbonylaminofenyl)etoxy]fenyl}- (S)-2-etoxypropánovú a sulfonylmočovinu
IL15903502A IL159035A0 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s) -2-ethoxy-3- [4- (2-{4-methane sulfonyl oxyphenyl}ethoxy) phenyl] propanoic acid or 3- {4- [2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl}- (s) -2-ethoxy propanoic acid and a sulfonylurea
BR0210127-0A BR0210127A (pt) 2001-06-01 2002-05-30 Composição farmacêutica, métodos de tratamento ou prevenção de diabetes e de tratamento da sìndrome de resistência à insulina, kit de partes, preparação combinada, e, método para a produção de um kit de partes
PCT/SE2002/001036 WO2002100413A1 (en) 2001-06-01 2002-05-30 A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- [4-(2-{4-METHANE SULFONYL OXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID OR 3-{4-[2-(4-TERT- BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL} -(s)-2-ETHOXY PROPANOIC ACID AND A SULONYLUREA
EP02736370A EP1399166A1 (en) 2001-06-01 2002-05-30 A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- 4-(2- 4-METHANE SULFONYL OXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID OR 3- 4- 2-(4-TERT- BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL -(s)-2-ETHOXY PROPANOIC ACID AND A SULONYLUREA
HU0401613A HUP0401613A3 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2)-{4-methane sulfonyl oxyphenyl}ethoxy)phenyl]propanoic acid or 3-{4-[2-(4-tert-butoxy carbonyl aminophenyl)ethoxy]phenyl}-(s)-2-ethoxy propanoic acid and a sulonylurea
MXPA03011010A MXPA03011010A (es) 2001-06-01 2002-05-30 Una combinacion farmaceutica que comprende ya sea acido (s)-2-etoxi-3[4-(2-{4-metansulfonil oxifenil}etoxi)fenil] propanoico o acido 3-{4-[2-(4-terbutoxicarbonilaminofenil) etoxi] fenil}-(s)-2-etoxi propanoico y una sulfonilurea.
CNB028149882A CN1250226C (zh) 2001-06-01 2002-05-30 一种包含(s)－2－乙氧基－3－[4－(2－{4－甲磺酰基氧基苯基}乙氧基)苯基]丙酸或3－{4－[2－(4－叔丁氧基羰基氨基苯基)乙氧基]苯基}－(s)－2－乙氧基丙酸和磺酰脲的联合药物
CZ20033235A CZ20033235A3 (cs) 2001-06-01 2002-05-30 Farmaceutická kombinace
NO20035235A NO20035235D0 (no) 2001-06-01 2003-11-25 Farmasöytisk kombinasjon omfattende enten (S) -2-etoksy-3- (4- (2- (4-metansulfonyloksyfenyl) etoksy) fenyl) propansyre eller 3- (4- (2- (4-tert-butoksykarbonylaminofenyl) etoksy) fenyl)
ZA200309263A ZA200309263B (en) 2001-06-01 2003-11-27 A pharmaceutical combination comprising either (S)-2-ethoxy-3- [4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl) propanoic acid or 3-{4-[2-(4-tert- butoxy carbonyl aminophenyl) ethoxyl phenyl} -(S)-2-ethoxy propanoic acid and a sulfonylurea.
IS7057A IS7057A (is) 2001-06-01 2003-11-28 Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3-[4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxýprópansýru og súlónýlþvagefni
CO03112113A CO5540382A2 (es) 2001-06-01 2003-12-23 UNA COMBINACION FARMACEUTICA QUE COMPRENDE UNO CUALQUIERA DE ACIDO (S)-2-ETOXI-3-(4-(2-(4-METANOSULFONIL OXIFENIL) ETOXI) FENIL) PROPANOICO O ACIDO 3-(4-(2-(4-TERTBUTOXI CARBONIL AMINOFENIL)ETOXI)FENIL)-(s)-2-ETOXI PROPANOICO Y UNA SULFONILUREA

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0101982A SE0101982D0 (sv) 2001-06-01 2001-06-01 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
SE0101982D0 true SE0101982D0 (sv) 2001-06-01

Family

ID=20284364

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0101982A SE0101982D0 (sv) 2001-06-01 2001-06-01 Pharmaceutical combination

Country Status (21)

Country Link
US (1) US20040157927A1 (xx)
EP (1) EP1399166A1 (xx)
JP (1) JP2004532891A (xx)
KR (1) KR20040007624A (xx)
CN (1) CN1250226C (xx)
BR (1) BR0210127A (xx)
CA (1) CA2448763A1 (xx)
CO (1) CO5540382A2 (xx)
CZ (1) CZ20033235A3 (xx)
EE (1) EE200300583A (xx)
HU (1) HUP0401613A3 (xx)
IL (1) IL159035A0 (xx)
IS (1) IS7057A (xx)
MX (1) MXPA03011010A (xx)
NO (1) NO20035235D0 (xx)
PL (1) PL367890A1 (xx)
RU (1) RU2003136157A (xx)
SE (1) SE0101982D0 (xx)
SK (1) SK14722003A3 (xx)
WO (1) WO2002100413A1 (xx)
ZA (1) ZA200309263B (xx)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008019169A (ja) * 2004-10-25 2008-01-31 Osaka Univ 新規ｐｐａｒ調節剤およびそのスクリーニング方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6552055B2 (en) * 1996-12-11 2003-04-22 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
SE9801990D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I

Also Published As

Publication number Publication date
JP2004532891A (ja) 2004-10-28
SK14722003A3 (sk) 2004-08-03
NO20035235D0 (no) 2003-11-25
CN1537008A (zh) 2004-10-13
PL367890A1 (en) 2005-03-07
ZA200309263B (en) 2005-03-11
KR20040007624A (ko) 2004-01-24
EP1399166A1 (en) 2004-03-24
BR0210127A (pt) 2004-06-08
EE200300583A (et) 2004-02-16
HUP0401613A2 (hu) 2004-11-29
CO5540382A2 (es) 2005-07-29
WO2002100413A1 (en) 2002-12-19
US20040157927A1 (en) 2004-08-12
IS7057A (is) 2003-11-28
IL159035A0 (en) 2004-05-12
HUP0401613A3 (en) 2007-11-28
CA2448763A1 (en) 2002-12-19
CN1250226C (zh) 2006-04-12
RU2003136157A (ru) 2005-05-20
CZ20033235A3 (cs) 2004-12-15
MXPA03011010A (es) 2004-02-27

Similar Documents

Publication Publication Date Title
NO2015022I1 (no) Edoksaban eller et salt derav, spesielt edoksabantosilat (ptoluensulfonat monohydrat) - se kravene 3, 4 og 5
IS6399A (is) Mulið form (S)-2-etoxý-3-[4-(2-{4-metansúlfonýloxýfenýl}etoxý)fenýl]própanónsýra
NO20013674D0 (no) Acetyleniske <alfa>-aminosyre-baserte sulfonamid- hydroksamsyre TACE-inhibitorer
BR0317715A (pt) Composições e processos de uso de collajolie
DE60335311D1 (de) Projektor, Informationsspeicherungsmedium und Bildprojektionssverfahren
BR9910913A (pt) Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, e, processo para a profilaxia e/ou tratamento de condições clìnicas associadas com resistência a insulina
DE60315097D1 (de) Projektionsobjektiv und Projektor
ATE341544T1 (de) Sulfonamide
BR0207509A (pt) Pirazolilpirimidinas
ATE449766T1 (de) Piperazinyl- und diazapanylbenzamide und- benzothioamide
EE200400023A (et) Uued sulfoonhappe derivaadid
DK1370543T3 (da) Bredspektrede 2-(substitueret amino) benzothiazol- sulfonamid-HIV-proteaseinhibitorer
SE0101982D0 (sv) Pharmaceutical combination
ES2571834T3 (es) Alquilsulfonamida quinolinas
SE0101981D0 (sv) Pharmaceutical combination
DE50103723D1 (de) 6-Spiegel-Mikrolithographie-Projektionsobjektiv
IS7058A (is) Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3-[4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxýprópansýru og bígúaníðlyf
BRPI0418226A (pt) preparação de cloridrato r-5-(2-(2-(2-etoxifenoxietilamino) propil-2-metoxibenzenossulfonamida de alta pureza quìmica
AU2003244922A1 (en) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-benzamide for treating pulmonary fibrosis
HUP0303027A2 (hu) Új benzoil-guanidin só és alkalmazása gyógyszerkészítmény előállítására
FR2821025B1 (fr) Brides d'echappement minces
DK1387683T3 (da) Hidtil ukendte saltformer eller krystallinske former af (2R)-anti-5-3-[4-(10,11-difluormethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy quinolin
ES1054247Y (es) Estuche para cd's
AU2002254271A1 (en) Novel salt and crystalline forms of (2r)-anti-5-{3-(4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl)-2-hydroxypropoxy}quinoline